Can Magnesium Lower Creatinine Levels? The Real Answer

No, magnesium does not lower creatinine levels. Not in the way the question intends. There is no trial showing that taking a magnesium supplement reduces serum creatinine, no plausible mechanism by which it would, and nothing in kidney guidelines that recommends magnesium as a way to bring a raised creatinine down. Creatinine is a waste product of muscle metabolism, cleared almost entirely by filtration, and its blood level reflects how much your muscles make against how well your kidneys filter. Magnesium changes neither of those things. If your creatinine is 1.6 mg/dL today, a magnesium capsule will not make it 1.3 mg/dL next month.

That is the whole answer to the literal question, and it takes one paragraph. The rest of this page exists because magnesium is genuinely more interesting than that, and because the more useful question is not whether it lowers a number but whether your magnesium status matters to your kidneys at all. It probably does, in ways that have nothing to do with creatinine. It also carries a specific and occasionally lethal danger once kidney function drops far enough, one that most supplement labels do not mention. If you want the broader picture on lowering creatinine naturally, or on what medicines actually reduce creatinine, those pages cover the wider ground. This one stays on magnesium.

Why magnesium cannot move creatinine

To see why the answer is no, you need to know what sets the number. Creatinine appears in your blood at a rate governed by muscle mass and diet, and disappears from it at a rate governed by glomerular filtration plus a small amount of tubular secretion. Those are the only two taps. Roughly one to two percent of the creatine stored in your muscles converts spontaneously to creatinine every day, a rate that does not care what supplements you take. The kidney then removes it. Blood level is the ratio between the two.

Magnesium sits outside both processes. It is not a substrate for creatine synthesis, it does not change the non-enzymatic conversion rate of creatine to creatinine, and it does not increase the number of functioning nephrons you have. It has no effect on tubular secretion of creatinine through the OCT2 and MATE transporters, which is the route that drugs like trimethoprim and cimetidine block. Nor does it interfere with the laboratory assay, so it will not artefactually lower a reading either. There is simply no lever for it to pull.

Read that expression and ask where magnesium would enter it. It does not appear in the numerator, because magnesium is not part of creatine synthesis or breakdown. It does not appear in the denominator, because magnesium supplementation does not increase glomerular filtration rate in humans. Anything that genuinely lowers creatinine has to do one of two things: reduce production, which means less muscle or less meat, or improve clearance, which means more functioning kidney or better perfusion. Magnesium does neither.

There is one narrow caveat, and it is worth stating precisely so nobody mistakes it for a loophole. If someone is severely magnesium depleted to the point of muscle weakness and cramping, correcting that deficiency might marginally change their physical activity and therefore their muscle turnover. This is a theoretical footnote, not a treatment effect, and it would be far too small to see on a report. Nobody has ever demonstrated it. Do not build a plan around it.

The same reasoning applies to every supplement in this category, which is why the honest answer to most of these questions is no. What changes across supplements is what happens after the no. With most, the story ends there. With magnesium, it starts.

Where the claim came from in the first place

Search engines are full of pages implying magnesium helps kidneys, and the claim did not appear out of nothing. It has three sources, and separating them explains a lot.

The first is the observational literature, which is real. Multiple cohort studies of people with chronic kidney disease have found that those with lower serum magnesium tend to lose function faster and have higher cardiovascular mortality. That is a genuine, repeatedly observed association. It is also an association, with all the interpretive trouble that carries, and it says nothing about creatinine specifically.

The second is the vascular calcification research, which is the most mechanistically interesting part of the whole field and gets covered properly further down. Magnesium demonstrably interferes with the formation of calcium-phosphate crystals in laboratory conditions, and calcification of arteries is one of the defining problems of advanced kidney disease. Put those two facts next to each other and a supplement marketing department writes itself a headline.

The third is straightforward confusion between magnesium and other things. People conflate it with potassium restriction, with alkalising agents such as sodium bicarbonate, and with the general idea that minerals are good for you. Some pages appear to have muddled magnesium with the mineral chelators used in phosphate binding, where magnesium carbonate genuinely is used in some products. None of that adds up to lowering creatinine.

The observational signal: low magnesium and faster decline

Here is where the topic earns its place. Across a number of cohort studies in people with chronic kidney disease, low serum magnesium has been associated with a steeper decline in filtration over time, with higher rates of progression to kidney failure, and with increased death from cardiovascular causes. The finding has turned up in different populations, in dialysis patients and pre-dialysis patients, and it has proved reasonably durable.

That consistency is what makes it worth attention. A single positive cohort study means little. A finding that keeps reappearing in different countries, different cohorts and different analytical approaches is harder to dismiss as noise, even when every one of those studies is observational.

Now the caution. Observational consistency is not causation, and there is a specific reason to be suspicious here. Serum magnesium tends to be lower in people who are malnourished, in people with poor appetite, in people with uncontrolled diabetes, and in people taking multiple medications for serious comorbidity. Every one of those is independently associated with worse kidney outcomes. A low magnesium may be a marker of being iller rather than a cause of getting worse. Statisticians call this confounding by indication and it is extremely difficult to fully remove from this kind of data.

There is a second complication that runs in the opposite direction. In advanced kidney disease, serum magnesium tends to rise, not fall, because excretion is impaired. So the sickest kidneys often come with higher magnesium, which means the association between low magnesium and bad outcomes is not simply tracking severity of kidney disease. That partial dissociation is one of the reasons researchers take the signal semi-seriously rather than dismissing it.

The left column is why nephrologists pay attention to magnesium at all. The right column is why they do not hand out supplements to everyone with a raised creatinine. Both columns are true simultaneously, and holding both is the intellectually honest position. If your creatinine is drifting up and you want to know what actually changes trajectory, treating high creatinine and lowering creatinine levels deal with the interventions that have evidence behind them.

The calcification story, which is the genuinely interesting part

People with advanced kidney disease do not usually die of kidney failure. They die of cardiovascular disease, at rates far above the general population, and the pattern of that disease is peculiar. It is not simply more atherosclerosis. It is calcification of the arterial wall itself, particularly the middle layer, which stiffens the vessel and raises the load on the heart. This process, sometimes called medial calcification, is one of the signature pathologies of chronic kidney disease and it is poorly addressed by conventional cardiovascular treatment.

The chemistry behind it is straightforward. As filtration falls, phosphate accumulates. Calcium and phosphate in solution above a certain concentration product begin to precipitate as calcium-phosphate. In the vessel wall, smooth muscle cells respond to that environment by behaving like bone-forming cells, laying down mineral in a tissue that should have none. The result is a pipe that has partly turned to stone.

Magnesium enters this story as a competitive interferer. It is chemically similar enough to calcium to be incorporated into the growing crystal lattice, and different enough that its presence disrupts the orderly growth of hydroxyapatite, the crystalline form calcium-phosphate eventually adopts. In laboratory systems, adding magnesium slows or prevents that crystallisation. Magnesium also appears to influence the cellular side, damping the switch that turns vascular smooth muscle cells into bone-like cells.

That figure is the single most useful idea on this page. The same mineral, the same dose, the same bottle, produces opposite risk profiles depending on where your filtration sits. Almost nothing else in nutrition behaves quite so cleanly as a function of one number.

The unresolved part is whether any of the calcification biology translates into clinical benefit from taking magnesium. Small studies have looked at whether magnesium supplementation slows the progression of coronary artery calcium scores in people with kidney disease, and results have been mixed and generally underpowered. Nobody has run the large, long, hard-endpoint trial that would settle it. Until somebody does, the mechanism remains a good hypothesis rather than a reason to swallow anything.

What the interventional evidence actually shows

Observational signal strong, mechanism plausible, trials thin. That is the honest three-word summary of magnesium in kidney disease, and it is worth spelling out what “thin” means, because the gap between a promising association and a proven treatment is where most nutritional claims die.

The trials that exist share the same limitations. They are small, often a few dozen to a couple of hundred participants. They are short, typically weeks to a year, when the outcome of interest unfolds over a decade. They use surrogate endpoints such as calcification scores, arterial stiffness measures or biochemical markers rather than events people care about, like heart attacks, dialysis initiation or death. And they are heterogeneous in the salt used, the dose, and the population studied, which makes pooling them difficult.

Some of those studies have shown favourable movement in surrogate markers. That is encouraging and it is why the research continues. It is not the same as knowing whether a person with an eGFR of 40 who takes magnesium for ten years does better than one who does not. Surrogate endpoints have an unhappy history in nephrology and cardiology, where interventions that improved a measurement went on to harm patients in outcome trials. Erythropoietin targets and certain calcium-based phosphate binders are both cautionary examples of exactly that pattern.

If you want a comparison that puts this in perspective, consider what does have solid outcome evidence in slowing kidney decline: blood pressure control, renin-angiotensin system blockade in proteinuric disease, SGLT2 inhibitors, glycaemic control in diabetes, and stopping smoking. Those interventions have been tested in thousands of people over years with hard endpoints. Magnesium is not in that category and pretending otherwise does readers a disservice. The NIDDK overview of chronic kidney disease sets out the interventions that carry that weight of evidence.

The drug angle: why low magnesium is so often the prescription’s fault

This is the part of the article most likely to change something in your life, and it gets far less attention than it deserves. A large share of low magnesium in people with kidney disease is caused by their own medication list, and it is correctable once somebody notices.

Proton pump inhibitors

Omeprazole, lansoprazole, pantoprazole, esomeprazole and the rest of the class reduce stomach acid, and reduced acid impairs intestinal magnesium absorption. The effect is well documented enough that regulators including the US Food and Drug Administration have issued formal safety communications about PPI-induced hypomagnesaemia. It typically takes months to years of continuous use to develop, which is precisely why it gets missed: the drug was started long ago and nobody connects it to a blood result now.

Two features make this clinically nasty. First, the magnesium loss can be severe enough to cause seizures, arrhythmias and tetany, not just a mildly low number. Second, it often drags potassium and calcium down with it, because magnesium depletion impairs the body’s ability to hold onto both, and those secondary deficiencies do not correct until the magnesium is fixed. A stubbornly low potassium or calcium that will not respond to replacement is a classic clue to an underlying magnesium problem.

PPIs are also among the most over-prescribed drug classes in existence, frequently continued for years after the original indication has passed. A great many people are on one because it was started during a hospital admission a decade ago. That is worth raising at a review, particularly since PPIs appear separately in the list of medications that can raise creatinine through interstitial nephritis.

Loop diuretics

Furosemide, bumetanide and torasemide act on the thick ascending limb of the loop of Henle, which happens to be where the majority of filtered magnesium is reabsorbed. Block transport there and magnesium leaves in the urine along with the sodium and water you intended to remove. Potassium and calcium go the same way.

People with kidney disease are often on loop diuretics for fluid overload, sometimes at high doses, sometimes for years. The magnesium wasting is a predictable pharmacological consequence rather than a rare side effect. It is not a reason to stop a diuretic that is keeping fluid off your lungs. It is a reason for somebody to check the level periodically.

Thiazides and thiazide-like diuretics

Bendroflumethiazide, hydrochlorothiazide, indapamide and chlortalidone act further along the tubule, in the distal convoluted tubule, which is where magnesium reabsorption is fine-tuned. They too cause renal magnesium wasting, generally more slowly than loop diuretics but over longer exposure, since thiazides are usually taken for blood pressure over decades.

The others

Look at that list next to a typical kidney clinic medication chart. A person with stage 3 CKD, hypertension, diabetes and reflux might easily be on a thiazide, a loop diuretic and a PPI simultaneously, with hyperglycaemia on top. Four magnesium-depleting exposures at once, none of them individually alarming, and a low result that reads as a mystery unless someone looks at the whole list. That is the case where checking a level and correcting it makes obvious sense.

One exit, and only one

Everything in the safety half of this article follows from a single anatomical fact. Magnesium leaves the body through the kidney. That is the regulated route, and there is no backup.

Your gut controls how much magnesium comes in, but only loosely, and it becomes proportionally less selective at higher intakes. Once magnesium is absorbed, the kidney does the real work. It filters magnesium at the glomerulus, reabsorbs the great majority of it along the tubule, and adjusts the final amount excreted according to need. In a healthy person, that regulation is precise. Eat more and you excrete more. Eat less and the kidney claws back nearly all of it. The blood level barely moves.

Take the kidney away and the whole system loses its regulator. There is no significant biliary excretion of magnesium, no exhalation route, no sweat pathway of any consequence. Skin loss is negligible. If the kidney cannot excrete it, absorbed magnesium accumulates, and the only thing standing between an intake and a rising blood level is how much your gut happens to absorb.

The compensation deserves a moment. As nephrons are lost, each remaining one excretes a larger fraction of the magnesium it filters, which is why serum magnesium often stays normal well into stage 3 kidney disease. That works until it does not. The reserve is finite, and once it is exhausted the relationship between intake and blood level becomes direct and unbuffered. Someone with an eGFR of 20 who takes a substantial magnesium load has very little between them and a rising level.

This is the same logic that governs potassium and phosphate in kidney disease, and readers who have already been told to watch those two will recognise the pattern immediately. Magnesium simply gets discussed less, partly because dietary magnesium is rarely enough to cause trouble on its own and partly because the dangerous sources are sitting in the bathroom cabinet rather than the fridge. To see roughly where your own filtration sits, the creatinine clearance calculator and the guide to calculating GFR from creatinine will both get you an estimate.

When the risk flips: hypermagnesaemia in advanced kidney disease

This is the safety core of the article, and it deserves to be read carefully by anyone whose eGFR is below 30 or who is caring for someone in that position.

Severe hypermagnesaemia is rare, and almost every case has the same two ingredients: impaired kidney function and an unusual magnesium exposure. In people with normal kidneys, the exposure alone almost never does it. In people with advanced kidney disease, the exposure does not need to be exotic. Over-the-counter products bought without a thought have caused fatal magnesium toxicity in patients with kidney failure, and the case reports of this go back decades.

What makes it dangerous is the combination of a low index of suspicion and a fast trajectory. Nobody suspects magnesium. It is not on a standard urgent blood panel in many hospitals, so it has to be specifically requested. The early symptoms are vague and easily attributed to the kidney disease itself. By the time the picture is unmistakable, the patient is in serious trouble, because at high levels magnesium blocks neuromuscular transmission and depresses cardiac conduction.

The bowel preparation problem specifically

One scenario recurs often enough to name. A person with advanced kidney disease is booked for a colonoscopy and given, or buys, a magnesium citrate bowel preparation. It works by drawing water into the bowel osmotically, which means a very large magnesium load is sitting in the intestine, and a proportion of it is absorbed. In someone who cannot excrete it, that single exposure can produce a dangerous level within hours. Serious and fatal cases have been reported. Modern preparation protocols avoid magnesium-based products in kidney impairment for exactly this reason, but the products remain freely purchasable and people do buy them.

The same applies to magnesium-containing enemas and to repeated doses of milk of magnesia for constipation, which is extremely common in this population because constipation itself is common, partly from fluid restriction and partly from phosphate binders.

What magnesium overload feels like, in order

Magnesium toxicity progresses in a reasonably predictable sequence as the level climbs, and knowing the order is useful because the early features are easy to write off.

The sequence matters more than any specific number, because the level at which each stage appears varies between people and depends on how quickly the rise occurred. A slow rise is tolerated better than a fast one. What is consistent is the order: gut and skin first, then blood pressure and consciousness, then reflexes, then muscle, then breathing, then heart.

Anyone with reduced kidney function who becomes unusually drowsy, weak or flushed after taking a magnesium-containing product should be assessed urgently and should say what they took. That last part is the bit people leave out, because a laxative does not feel like information a doctor needs.

Laxatives, antacids and Epsom salts: the exposures nobody counts

Ask someone with kidney disease whether they take magnesium and they will usually say no. Ask what they take for constipation or indigestion and the answer changes. The largest magnesium exposures in this population do not come from bottles marked “magnesium supplement”.

Two things follow. First, if you have reduced kidney function, reading the full ingredient list of anything you buy over the counter is a genuinely worthwhile habit, and the word to look for is magnesium in any compound form. Second, constipation in kidney disease should be managed with something other than a magnesium-based laxative, and there are plenty of alternatives that a pharmacist or doctor can suggest.

Epsom salt baths are worth separating out, because they generate a lot of anxiety and very little actual risk. Transdermal absorption of magnesium through intact skin is minimal and the evidence that it raises blood levels meaningfully is weak. The danger with Epsom salts is oral use, which people do because old home-remedy advice recommends it as a purgative. A bag of Epsom salts in the bathroom is not a hazard. A spoonful of it in a glass of water, in someone with an eGFR of 18, potentially is.

Salt forms, and how much of the pill is actually magnesium

If you look at two bottles both saying 400 mg, they may contain wildly different amounts of magnesium. The number on the front is often the weight of the compound, not the element. Since magnesium is a light atom bonded to much heavier partners in most of these salts, the difference is large.

These percentages are simple chemistry, calculated from molecular weights, and they are fixed:

Work through a worked example. A capsule containing 400 mg of magnesium oxide delivers about 241 mg of elemental magnesium. A capsule containing 400 mg of magnesium citrate delivers about 65 mg. Same label weight, nearly a fourfold difference in the element. Then absorption differs on top of that, and oxide is absorbed poorly while citrate is absorbed well, which narrows the practical gap but in an unpredictable direction. This is one reason comparing supplement doses across products is close to meaningless without reading the small print.

The laxative effect is the other axis worth understanding, because it is not a side effect so much as the same property viewed differently. Poorly absorbed, osmotically active magnesium salts pull water into the bowel. That is precisely what makes magnesium hydroxide and magnesium citrate effective laxatives, and it is also what causes the loose stools people complain about with cheap magnesium oxide supplements. Glycinate and other chelated forms cause less of it because more of the magnesium is absorbed rather than sitting in the lumen.

For someone with normal kidneys, all of this is a matter of tolerability and cost. For someone with an eGFR of 25, it is a matter of how much magnesium is crossing the gut wall into a body that cannot get rid of it, which is a different question with a different weight attached.

Food versus supplements, which are not the same conversation

Dietary magnesium and supplemental magnesium behave differently enough that lumping them together causes real confusion. Almost everything alarming in this article is about supplements and medicinal products. Very little of it is about food.

Three reasons for that. Food delivers magnesium slowly, mixed into a meal, in amounts that rarely exceed a few hundred milligrams across a whole day. Absorption from food is partial and self-limiting, dropping as intake rises. And nobody eats 2,000 mg of magnesium at once from spinach, whereas a bowel preparation delivers that kind of load in a single glass. Reported cases of magnesium toxicity from ordinary food intake in people with kidney disease are, as far as the published literature goes, essentially absent.

Reference intakes for adults sit around 400 to 420 mg daily for men and 310 to 320 mg for women, with more in pregnancy. Those are targets for the general population, not prescriptions, and they are not adjusted for kidney disease. Most people in Western countries fall somewhat short of them, which is one reason magnesium supplements sell so well.

The potassium collision

Here is a tension that renal dietitians deal with constantly and that almost no general-audience article about magnesium mentions.

Magnesium, potassium and phosphate are all concentrated in the same class of foods: seeds, nuts, pulses, whole grains, leafy greens and certain fruits. They are stored together in plant tissue because plants need all three. So the dietary advice that reduces potassium in advanced kidney disease also, inevitably, reduces magnesium. A person carefully following a low-potassium diet for a year is very likely eating less magnesium than they were before, and nobody told them so.

That is one plausible, though unproven, explanation for part of the low-magnesium signal in CKD cohorts. The people with the most advanced disease are the ones on the strictest potassium restriction, and they are also the ones with the lowest dietary magnesium.

That last row is the problem in miniature. The refined grains that make a low-potassium diet easier are the same ones stripped of magnesium during milling. The diet gets safer for potassium and quietly worse for magnesium, and neither the patient nor the general practitioner necessarily notices.

There is no clean solution to this and it would be dishonest to invent one. What a renal dietitian actually does is work out where in an individual diet magnesium can be added without pushing potassium past what that person’s kidneys can handle, which depends entirely on their filtration, their potassium results and their medications. It is individual arithmetic, not a rule. If you are on a potassium-restricted diet and your magnesium is low, that is a conversation for a renal dietitian rather than a supermarket decision. Related reading on individual foods sits at bananas and kidney health, peanuts, and coconut water, all of which run into the same potassium arithmetic.

What a serum magnesium test does and does not tell you

You will probably be offered a serum magnesium at some point in this conversation, and it is worth knowing what that number is and is not.

Total body magnesium in an adult is roughly 24 grams. About 60 percent of it is locked in bone. Most of the remainder is inside cells, where it acts as a cofactor for hundreds of enzymes, particularly everything involving ATP. Only around one percent of the body’s magnesium is in blood plasma at any moment, which works out at something like 240 milligrams in the entire extracellular compartment.

So the test measures one percent of the pool and infers the other ninety-nine. That is an inherently limited exercise, and it fails in a specific direction: it is possible to be genuinely magnesium depleted at the tissue level while your serum magnesium reads normal, because the body defends the plasma concentration by pulling magnesium out of bone and cells. A normal result does not exclude depletion. This is a recognised limitation, not a fringe view.

Typical adult reference ranges run around 0.7 to 1.0 mmol/L, which converts to roughly 1.7 to 2.4 mg/dL, though laboratories vary and you should read the range printed alongside your own result rather than any range quoted online. Around a quarter to a third of circulating magnesium is bound to albumin, so a low albumin can pull the total magnesium down without the biologically active ionised fraction being low at all. Ionised magnesium assays exist but are not routinely available in most hospitals.

Distinguishing gut loss from kidney loss

If magnesium is low, the useful next question is where it is going. The kidney answers it. If the body is short of magnesium, healthy kidneys should be excreting almost none, so finding magnesium in the urine tells you the kidney is the leak. This is measured either as a 24-hour urinary magnesium or, more conveniently, as a fractional excretion calculated from a spot sample, which is where creatinine reappears in the story:

The 0.7 factor is there because only about 70 percent of plasma magnesium is unbound and therefore available for filtration. A high fractional excretion in the face of a low blood level points to renal wasting, which redirects attention to diuretics, calcineurin inhibitors, tubular disorders or poorly controlled diabetes. A low fractional excretion points to the gut, which redirects attention to PPIs, malabsorption or diarrhoea. Urine creatinine is doing the same normalising job it does in protein-creatinine ratios, and the concept is explained further in creatinine in urine.

Note what that calculation does not do. It does not tell you anything about your creatinine, and a magnesium result has no bearing on how a raised creatinine should be interpreted. The two tests share a formula and nothing else.

What to actually ask your doctor

Most people arrive at this topic having read a supplement page and wanting to know whether to buy something. That is the wrong question to bring to an appointment. These are better ones.

None of those questions are about lowering creatinine, and that is the point. Your creatinine is a filtration marker, interpreted alongside your eGFR, your urine albumin and your trend over time. The MedlinePlus guide to the creatinine test covers what the measurement represents, and what creatinine is explains the molecule itself. Magnesium sits in a different part of the chart entirely.

Mistakes worth avoiding

Related reading across the cluster: creatinine in stage 3 kidney disease, creatinine in stage 4 kidney disease, when to worry about creatinine levels, what a normal creatinine level is, how to improve creatinine levels, creatinine versus creatine, and clearance in drug dosing, which matters because several magnesium-wasting drugs are themselves dose-adjusted by kidney function.

Magnesium and creatinine: frequently asked questions